Bulletin of Experimental Biology and Medicine

, Volume 164, Issue 5, pp 617–619 | Cite as

Experimental Analysis of the Efficacy of Dihydroquercetin on the Model of Chronic Nonbacterial Inflammation of the Prostatic Gland

  • T. G. Borovskaya
  • S. I. Kamalova
  • M. E. Polyektova
  • V. A. Mashanova
  • A. V. Vychuzhanina
  • S. I. Kseneva
  • M. B. Plotnikov
  • V. E. Goldberg
Article
  • 12 Downloads

We studied the efficiency of dihydroquercetin on the model of chronic nonbacterial inflammation of the prostatic gland in rats. It was found that administration of dihydroquercetin was followed by a significant decrease in the area of the connective tissue in the prostatic gland to initial levels, which attested to antifibrotic properties of this oxidant. Additionally, the substance prevented the development of atrophy of acinus epithelium. After administration of reference drug Prostamol Uno, only moderate antifibrotic effects were observed.

Key Words

chronic nonbacterial prostatitis rats dihydroquercetin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bozhedomov VA. Chronic prostatitis: a new paradigm of treatment. Urologiya. 2016;(S3):78-90. Russian.Google Scholar
  2. 2.
    Borovskaya TG, Krivova NA, Zaeva OB, Fomina TI, Kamalova SI, Poluektova ME, Vychuzhanina AV, Shchemerova YA, Grigor’eva VA, Goldberg VE, Plotnikov MB. Dihydroquercetin effects on the morphology and antioxidant/prooxidant balance of the prostate in rats with sulpiride-induced benign hyperplasia. Bull. Exp. Biol. Med. 2015;158(4):513-516.CrossRefPubMedGoogle Scholar
  3. 3.
    Borovskaya TG, Fomina TI, Durnev AD, Udut VV, Pakhomova AV, Yurnazov ZA, Dygai AM. Guidelines for preclinical study of prostate-tropic activity of new drugs. Manual for Preclinical Studies of New Pharmacological Substances. Mironov AN, ed. Moscow, 2013. Part I, p. 727-739. Russian.Google Scholar
  4. 4.
    Savelieva KV, Borovskaya TG, Kheyfets IA, Dugina JL, Sergeeva SA, Epstein OI. Comparative study of pharmacological activity of afala on the model of hormone-induced prostatitis in rats. Bull. Exp. Biol. Med. 2007;144(5):699-701.CrossRefPubMedGoogle Scholar
  5. 5.
    Seregin SP, Bratchikov OI, Konoplya AI, Shestakov SG, Dolzhenkov SD, Novikob AV, Shatokhin MN, Kotov AV. Effect of Prostamol UNO on oxidative and local immune status in patients with benign prostate hyperplasia and chronic prostatitis. Urologiya. 2002;(4):14-16. Russian.Google Scholar
  6. 6.
    Tyuzikov IA. Chronic pelvic pain in men: optimization of pathogenetic pharmacotherapy from the standpoint of an interdisciplinary approach. Russ. Med. Zh. 2016;24(23):1535-1541. Russian.Google Scholar
  7. 7.
    Shatohin MN, Konoplja AI, Teodorovich OV, Krasnov AV, Mavrin MJu. Correction of immune and metabolic disorders in chronic prostatitis. Immunpatol., Allergol., Infektol. 2011;(4):6-12. Russian.Google Scholar
  8. 8.
    Shchegol’kova AM, Belyakin SA, Shakula AV, Klimko VV, Yaroshenko VP, Dergacheva LI. Medical rehabilitation of patients with coronary heart disease after coronary artery bypass surgery with dihydroquercetin support. Vestn. Vosstanovit. Med. 2007;(3):93-96. Russian.Google Scholar
  9. 9.
    Guo H, Zhang X, Cui Y, Zhou H, Xu D, Shan T, Zhang F, Guo Y, Chen Y, Wu D. Taxifolin protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Toxicol. Appl. Pharmacol. 2015;287(2):168-177.CrossRefPubMedGoogle Scholar
  10. 10.
    Morgia G, Mucciardi G, Galì A, Madonia M, Marchese F, Di Benedetto A, Romano G, Bonvissuto G, Castelli T, Macchione L, Magno C. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study. Urol. Int. 2010;84(4):400-406.CrossRefPubMedGoogle Scholar
  11. 11.
    Polackwich AS, Shoskes DA. Chronic prostatitis chronic pelvic pain syndrome: a review of evaluation and therapy. Prostate Cancer Prostatic Dis. 2016;19(2):132-138.CrossRefPubMedGoogle Scholar
  12. 12.
    Topal F, Nar M, Gocer H, Kalin P, Kocyigit UM, Gülçin İ, Alwasel SH. Antioxidant activity of taxifolin: an activity structure relationship. J. Enzyme Inhib. Med. Chem. 2015;31(4):674-683.PubMedGoogle Scholar
  13. 13.
    Videčnik Zorman J, Matičič M, Jeverica S, Smrkolj T. Diagnosis and treatment of bacterial prostatitis. Acta Dermatovenerol. Apl. Pannonica Adriat. 2015;24(2):25-29.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • T. G. Borovskaya
    • 1
  • S. I. Kamalova
    • 1
  • M. E. Polyektova
    • 1
  • V. A. Mashanova
    • 1
  • A. V. Vychuzhanina
    • 1
  • S. I. Kseneva
    • 1
  • M. B. Plotnikov
    • 1
  • V. E. Goldberg
    • 2
  1. 1.E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Medical Research CenterRussian Academy of SciencesMoscowRussia
  2. 2.Tomsk Research Institute of OncologyTomsk National Medical Research CenterTomskRussia

Personalised recommendations